• Filter By:
• Specialty
• Source
• Condition
• Cancer
• Infectious Disease
• Drug
• Training
• Management
• Procedure
• Therapy
• Vaccine
• Nutrition
• Country

Aspirin in diabetic patients at primary prevention: insights of the VITAL cohort
ConclusionsThe VITAL data confirmed diabetes as an important risk factor for cardiovascular events in a contemporary cohort but did not show cardiovascular benefits of aspirin in primary prevention among people with diabetes who were shown to be at higher risk of cardiovascular events.
Source: Journal of Endocrinological Investigation - June 15, 2023 Category: Endocrinology Source Type: research

RSSDI consensus recommendations for dyslipidemia management in diabetes mellitus
AbstractDiabetic dyslipidemia is characterised by low HDL-C and high triglyceride levels. Unlike the Caucasian population, though LDL-C levels are not very high, there is a preponderance of more atherogenic small, dense LDL particles among Indians. Furthermore, apo B levels are elevated. This, unique ‘atherogenic dyslipidemia’, is frequently encountered in South Asians with diabetes. People with type 2 diabetes are considered to be at high risk for vascular events. Hence, irrespective of other risk factors such as age, male gender, hypertension, family history, smoking, obesity, and polycyst ic ovary syndrome in women,...
Source: International Journal of Diabetes in Developing Countries - April 7, 2022 Category: Endocrinology Source Type: research

Myocardial Infarction, Stroke, and All-Cause Mortality According to Low-Density Lipoprotein Cholesterol Level in the Elderly, a Nationwide Study
CONCLUSION: Among the elderly, lower LDL-C was associated with decreased risks of MI and stroke. Lower LDL-C achieved by statins in the elderly was associated with a decreased risk of all-cause death during follow-up, suggesting that LDL-C paradox for the premature death risk in the elderly should not be applied to statin users. Intensive statin therapy should not be hesitated for older adults with cardiovascular risk factors including diabetes.PMID:35255552 | DOI:10.4093/dmj.2021.0225
Source: Diabetes and Metabolism Journal - March 7, 2022 Category: Endocrinology Authors: You-Bin Lee Minji Koo Eunjin Noh Soon Young Hwang Jung A Kim Eun Roh So-Hyeon Hong Kyung Mook Choi Sei Hyun Baik Geum Joon Cho Hye Jin Yoo Source Type: research

Major adverse cardiovascular and limb events in patients with diabetes treated with GLP-1 receptor agonists vs DPP-4 inhibitors
Conclusions/interpretationIn individuals with diabetes, the use of GLP1RAs was associated with significantly lower risks of major adverse limb events when compared with the use of DPP4is. The reduction in risk was driven largely by reduced rate of amputations. Moreover, treatment with GLP1RAs was also associated with lower risks of cardiovascular death, non-fatal stroke, non-fatal myocardial infarction and death from any cause. However, some unexplored confounding factors may exist in this observation study and future large-scale randomised controlled trials are needed.Graphical abstract
Source: Diabetologia - August 24, 2021 Category: Endocrinology Source Type: research

Expert position statements: comparison of recommendations for the care of adults and youth with elevated lipoprotein(a)
Purpose of review Summarize recent recommendations on clinical management of adults and youth with elevated lipoprotein(a) [Lp(a)] who are at-risk of or affected by cardiovascular disease (CVD). Recent findings There is ample evidence to support elevated Lp(a) levels, present in approximately 20% of the general population, as a causal, independent risk factor for CVD and its role as a significant risk enhancer. Several guidelines and position statements have been published to assist in the identification, treatment and follow-up of adults with elevated levels of Lp(a). There is growing interest in Lp(a) screenin...
Source: Current Opinion in Endocrinology, Diabetes and Obesity - March 2, 2021 Category: Endocrinology Tags: LIPIDS: Edited by Gerald F. Watts Source Type: research

Stroke in the patient with diabetes (Part 2) – Prevention and the effects of glucose lowering therapies
There is a higher incidence of stroke in both the type 2 diabetic and the non-diabetic insulin resistant patient which is accompanied by higher morbidity and mortality. Stroke primary prevention can be achieved by controlling atrial fibrillation and hypertension, and the utilization of statins and anticoagulant therapies. Utilizing pioglitazone and GLP-1 receptor agonists reduce the risk of stroke while the utilization of metformin, α-glucosidase inhibitors, DPP-4 and SGLT-2 inhibitors have no effect.
Source: Diabetes Research and Clinical Practice - May 11, 2020 Category: Endocrinology Authors: David S.H. Bell, Edison Goncalves Tags: Review Source Type: research

Stroke in the patient with diabetes (Part 2) -Prevention and the effects of glucose lowering therapies
There is a higher incidence of stroke in both the type 2 diabetic and the non-diabetic insulin resistant patient which is accompanied by higher morbidity and mortality. Stroke primary prevention can be achieved by controlling atrial fibrillation and hypertension, and the utilization of statins and anticoagulant therapies. Utilizing pioglitazone and GLP-1 receptor agonists reduce the risk of stroke while the utilization of metformin, α-glucosidase inhibitors, DPP-4 and SGLT-2 inhibitors have no effect.
Source: Diabetes Research and Clinical Practice - May 11, 2020 Category: Endocrinology Authors: David S.H. Bell, Edison Goncalves Tags: Review Source Type: research

Intensive LDL cholesterol-lowering treatment beyond current recommendations for the prevention of major vascular events: a systematic review and meta-analysis of randomised trials including 327 037 participants
Publication date: January 2020Source: The Lancet Diabetes & Endocrinology, Volume 8, Issue 1Author(s): Nelson Wang, Jordan Fulcher, Nishan Abeysuriya, Laura Park, Shejil Kumar, Gian Luca Di Tanna, Ian Wilcox, Anthony Keech, Anthony Rodgers, Sean LalSummaryBackgroundThe benefits of LDL cholesterol-lowering treatment for the prevention of atherosclerotic cardiovascular disease are well established. However, the extent to which these effects differ by baseline LDL cholesterol, atherosclerotic cardiovascular disease risk, and the presence of comorbidities remains uncertain.MethodsWe did a systematic literature search (MEDLINE,...
Source: The Lancet Diabetes and Endocrinology - December 18, 2019 Category: Endocrinology Source Type: research

Lowering Targeted Atherogenic Lipoprotein Cholesterol Goals for Patients at “Extreme” ASCVD Risk
AbstractPurpose of ReviewTo review randomized interventional clinical and imaging trials that support lower targeted atherogenic lipoprotein cholesterol goals in “extreme” and “very high” atherosclerotic cardiovascular disease (ASCVD) risk settings. Major atherosclerotic cardiovascular event (MACE) prevention among the highest risk patients with ASCVD requires aggressive management of global risks, including lowering of the fundamental atherogenic ap olipoprotein B-associated lipoprotein cholesterol particles [i.e., triglyceride-rich lipoprotein remnant cholesterol, low-density lipoprotein cholesterol (LDL-C), and ...
Source: Current Diabetes Reports - November 20, 2019 Category: Endocrinology Source Type: research

Pre-existing Depression among Newly Diagnosed Dyslipidemia Patients and Cardiovascular Disease Risk.
CONCLUSION: Dyslipidemia patients with pre-existing depression had increased risk for CVD. Future studies that determine CVD risk after management of depression among dyslipidemia patients are needed. PMID: 31701694 [PubMed - as supplied by publisher]
Source: Diabetes and Metabolism Journal - November 10, 2019 Category: Endocrinology Tags: Diabetes Metab J Source Type: research

Effects of alirocumab on cardiovascular and metabolic outcomes after acute coronary syndrome in patients with or without diabetes: a prespecified analysis of the ODYSSEY OUTCOMES randomised controlled trial
Publication date: Available online 1 July 2019Source: The Lancet Diabetes & EndocrinologyAuthor(s): Kausik K Ray, Helen M Colhoun, Michael Szarek, Marie Baccara-Dinet, Deepak L Bhatt, Vera A Bittner, Andrzej J Budaj, Rafael Diaz, Shaun G Goodman, Corinne Hanotin, Robert A Harrington, J Wouter Jukema, Virginie Loizeau, Renato D Lopes, Angèle Moryusef, Jan Murin, Robert Pordy, Arsen D Ristic, Matthew T Roe, José TuñónSummaryBackgroundAfter acute coronary syndrome, diabetes conveys an excess risk of ischaemic cardiovascular events. A reduction in mean LDL cholesterol to 1·4–1·8 mmol/L with ezetimibe or statins reduces...
Source: The Lancet Diabetes and Endocrinology - July 2, 2019 Category: Endocrinology Source Type: research

Pages: 1  2  3